NEWS JACC in a FLASH
Featured topics in the current and recent
issues of the JACC family of journals
ence and extent of atherosclerosis were
associated with the extent of secondhand tobacco smoke exposure even
when adjusted for other risk factors,
further demonstrating the causal relationship of secondhand tobacco smoke
exposure and coronary disease.”
In an accompanying editorial comment, Khurram Nasir, MD, MPH, and
Jaideep Patel, MD, note that “although
the study sample size is modest, the initial insights are astounding.” They add
that the study provides an opportunity
to caution the public against the effects
of secondhand smoke and to encourage
policymakers to further advance efforts
to implement smoke-free laws, especially in public spaces.
Yankelevitz DF, Cham MD, Hecht H, et al.
J Am Coll Cardiol Img. 2016;doi:10.1016/j.
More to Secondhand Smoke Than
There may be a greater association
between the extent of secondhand
tobacco smoke exposure and the
extent of atherosclerosis than previously thought, according to the results
of research presented at AHA 2016
and simultaneously published in JACC:
David F. Yankelevitz, MD, et al.,
analyzed responses from questionnaires of 268 never-smokers between
the ages of 40 – 80 on their exposure to
secondhand tobacco smoke during their
lifetime. Researchers used low-dose
nongated computed tomographic (CT)
scans, followed by CT angiography, to
derive ordinal coronary artery calcium
scores, which were then evaluated for
characteristics of atherosclerosis.
The results of the study show that
coronary atherosclerosis was noted in
48%of patients and was more frequent
with low to moderate and high vs.
minimal secondhand tobacco smoke
exposure (48% and 69% vs. 25%).
Further, as the reported exposure to
secondhand tobacco smoke increased,
the percentage of major vessel with any
plaque or stenosis increased.
The authors conclude that “the pres-
A Closer Look
at Allogenic vs.
Allogenic human mesenchymal stem
cells may be safe and effective in patients with non-ischemic dilated cardiomyopathy compared to autologous
stem cells, according to the results of
the POSEIDON-DCM Trial presented
during AHA 2016 and simultaneously
published in JACC.
Joshua M. Hare, MD, et al., randomized 37 patients with non-ischemic
dilated cardiomyopathy to receive either
allogenic or autologous bone marrowderived human mesenchymal stem cells
by transendocardial stem cell injection.
Patients were evaluated at baseline, 30days, 3, 6 and 12 months for safety and
The results of the study show
that the rate of major adverse cardiac
events was lower in patients who re-
ceived allogenic stem cells versus autologous. Ejection fraction increased
in the allogenic group by 8 units, compared to 5.4 units in the autologous
group. Further, at 12-months, the incidence of serious adverse events was
28.2% in the allogenic group versus
63.5% i n the autologous group.
“The findings must be viewed as
preliminary given the small number of
patients enrolled,” commented Kim A.
Eagle, MD, editor-in-chief of ACC.org.
Hare JM, DiFede DL, Castellanos AM, et
al. J Am Coll Cardiol. 2016;doi:10.1016/j.
Does A Focus
on 30-Day HF
Quality of Care?
Quality of care and clinical outcomes
were comparable among hospitals with
high vs. low risk-adjusted 30-day heart
failure (HF) readmission rates, according to the results of research presented
during AHA 2016 and simultaneously
published in JACC: Heart Failure. The
findings raise questions about the impacts of the Centers for Medicare and
Medicaid Services (CMS) 30-day readmission metric on patient outcomes
and quality of care.
Researchers analyzed data from
171 centers enrolled in the GWTG-HF
Registry linked to Medicare claims
from July 2008 to June 2011. Publically
available data on HF-excess readmission ratio in 2013 were stratified into
two groups based on low vs. high
risk-adjusted readmission rates. Care
quality, in-hospital, and one-year clinical
outcomes were compared across the
two groups in unadjusted and multivariable adjusted analysis.
Overall results found that 84 centers
(49.%) had higher-than-expected risk-